Allergan plc (NYSE:AGN) shares reached a new 52-week low during trading on Friday . The company traded as low as $158.21 and last traded at $158.74, with a volume of 2626172 shares trading hands. The stock had previously closed at $164.20.

A number of research firms have commented on AGN. Cowen restated a “buy” rating on shares of Allergan in a research note on Thursday, October 12th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $275.00 price target on shares of Allergan in a research note on Monday, October 16th. Wells Fargo & Co set a $276.00 price target on shares of Allergan and gave the stock a “buy” rating in a research note on Friday, October 13th. Piper Jaffray Companies set a $227.00 price target on shares of Allergan and gave the stock a “hold” rating in a research note on Friday, October 13th. Finally, Cantor Fitzgerald set a $231.00 price target on shares of Allergan and gave the stock a “hold” rating in a research note on Thursday, October 12th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $227.23.

The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08. The company has a market cap of $54,610.00, a PE ratio of -13.58, a price-to-earnings-growth ratio of 1.26 and a beta of 1.19.

Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The company had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period in the prior year, the business posted $3.90 earnings per share. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. sell-side analysts expect that Allergan plc will post 15.44 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.77%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is -23.35%.

In other Allergan news, Director Chris W. Bodine purchased 3,030 shares of Allergan stock in a transaction on Thursday, December 7th. The shares were bought at an average price of $164.77 per share, with a total value of $499,253.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Brent L. Saunders purchased 4,600 shares of Allergan stock in a transaction on Wednesday, December 6th. The stock was acquired at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Insiders acquired 17,630 shares of company stock worth $2,890,057 in the last ninety days. Insiders own 0.36% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Edgewood Management LLC lifted its holdings in shares of Allergan by 24.3% in the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Baupost Group LLC MA lifted its holdings in shares of Allergan by 21.9% in the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after purchasing an additional 531,600 shares in the last quarter. Parnassus Investments CA lifted its holdings in shares of Allergan by 20.4% in the fourth quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock valued at $353,633,000 after purchasing an additional 365,914 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in shares of Allergan by 1.0% in the third quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after purchasing an additional 17,068 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Allergan by 13.6% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,763,209 shares of the company’s stock valued at $288,426,000 after purchasing an additional 210,962 shares in the last quarter. 80.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Allergan (AGN) Sets New 52-Week Low at $158.21” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/allergan-agn-sets-new-52-week-low-at-158-21/1855837.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.